Core Viewpoint - A class action lawsuit has been filed against Picard Medical, Inc. (PMI) for alleged fraudulent activities affecting investors who purchased shares between September 2, 2025, and October 31, 2025 [2][7]. Allegation Details - The lawsuit claims that Picard failed to disclose critical information, including involvement in a fraudulent stock promotion scheme, the use of offshore accounts for share dumping, and omissions in public statements regarding false rumors and artificial trading activity [7]. Stock Performance - On October 24, 2025, Picard's stock price plummeted by 70%, dropping to $3.99 per share, and has since continued to decline to approximately $2.00 per share [7]. Legal Process - Investors have until April 3, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Contact Information - Investors seeking more information or wishing to discuss their legal rights can contact Bragar Eagel & Squire, P.C. at (212) 355-4648 or via email [4][8].

Core Viewpoint - A class action lawsuit has been filed against Richtech Robotics Inc. for allegedly making false statements regarding its relationship with Microsoft, leading to significant investor losses during the specified class period [2][7]. Allegation Details - The lawsuit claims that Richtech misrepresented its collaborative and commercial relationship with Microsoft, which was not true. This misrepresentation resulted in materially false and misleading statements about the company's business and prospects [7]. Market Reaction - Following the publication of a critical report questioning Richtech's Microsoft collaboration, the company's stock fell by 20.87% on January 29, 2026, indicating a significant market reaction to the news [7]. Legal Process - Investors who purchased Richtech securities between January 27, 2026, and January 29, 2026, have until April 3, 2026, to apply to be appointed as lead plaintiff in the lawsuit [2]. Contact Information - Investors seeking more information or wishing to discuss their legal rights can contact Bragar Eagel & Squire, P.C. directly [4][8].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. for failing to disclose that strong sales results were due to excess inventory accumulation rather than increased consumer demand, leading to a significant stock price decline after disappointing financial results were announced [7]. Group 1: Allegation Details - The lawsuit claims that BellRing's management did not inform investors that the strong sales figures were misleading, as they were primarily driven by customers building up inventory to avoid previous product shortages [7]. - Following the resolution of supply issues, customers began to destock, resulting in a reduction of new orders and revealing weakened demand due to competitive pressures [7]. Group 2: Financial Impact - On August 4, 2025, BellRing reported a disappointing fiscal Q3 2025 outlook, narrowing its net sales forecast to a range of $2.28 billion to $2.32 billion [7]. - The announcement led to a significant drop in BellRing's stock price, which fell by $17.46 per share, or nearly 33%, from $53.64 on August 4, 2025, to $36.18 on August 5, 2025 [7]. Group 3: Legal Proceedings - Investors who purchased BellRing securities between November 19, 2024, and August 4, 2025, are encouraged to contact the law firm Bragar Eagel & Squire to discuss their legal rights and options [4][6]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is March 23, 2026 [7].

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its Phase 3 PALISADE-3 trial of fasedienol, leading to significant investor losses [2][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, inclusive [2]. - Investors have until March 16, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Vistagen made overwhelmingly positive statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial [7]. - On December 17, 2025, Vistagen announced that the PALISADE-3 study did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline from $4.36 to $0.86, a drop of over 80% [7]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the case are encouraged to contact Bragar Eagel & Squire for further assistance [4].

Core Viewpoint - A class action lawsuit has been filed against Fermi, Inc. for allegedly making materially false and misleading statements regarding its business operations and prospects, particularly concerning the Project Matador campus [4][7]. Allegation Details - The lawsuit claims that Fermi overstated tenant demand for its Project Matador campus [4]. - It is alleged that the company did not adequately disclose its reliance on a single tenant's funding commitment for the construction of Project Matador [4]. - There is a significant risk that the tenant could terminate its funding commitment, which was not disclosed [4]. - As a result of these issues, the positive statements made by the defendants about the company's business were misleading and lacked a reasonable basis [4]. Next Steps - Investors who purchased Fermi shares and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [5][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is March 6, 2026 [7].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its competitive position and sales performance in the EP manufacturing market [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Integer common stock between July 25, 2024, and October 22, 2025, inclusive [2]. - Investors have until February 9, 2026, to apply to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that the company materially overstated its competitive position in the EP manufacturing market [3]. - It claims that despite the company's assertions of strong customer demand visibility, there was a sustained deterioration in sales for two of its EP devices [3]. - The company mischaracterized its EP devices as a long-term growth driver for its C&V segment, leading to materially false and misleading statements about its business and prospects [3]. Group 3: Next Steps for Investors - Investors who purchased Integer shares and suffered losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4].

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. for allegedly making false and misleading statements regarding its financial guidance and business operations during the Class Period from February 26, 2025, to August 4, 2025 [3][7]. Allegation Details - The lawsuit claims that Agilon's defendants issued guidance for 2025 that they knew or should have known was unattainable due to significant industry challenges [3]. - It is alleged that the defendants overstated the immediate financial benefits from strategic actions taken to mitigate risks [3]. - As a result, the statements made about Agilon's business, operations, and future prospects were materially false and misleading throughout the Class Period [3]. Next Steps - Investors who purchased Agilon shares and experienced losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is March 2, 2026 [7].

Core Viewpoint - A class action lawsuit has been filed against F5, Inc. for allegedly providing misleading statements regarding its security capabilities, which led to significant financial losses for investors during the specified class period [2][8]. Group 1: Allegations - The lawsuit claims that F5 made overwhelmingly positive statements while concealing material adverse facts about its security capabilities, particularly regarding a significant security breach affecting key offerings [8]. - The breach was revealed to have a substantial impact on F5's ability to capitalize on the security market, leading to reduced sales and increased expenses for remediation efforts [8]. Group 2: Financial Impact - On October 27, 2025, F5 announced fourth quarter fiscal year 2025 results that fell significantly below market growth expectations for fiscal 2026, primarily due to the security breach [8]. - Following the announcement, F5's stock price dropped from $290.41 per share to $258.76 per share, marking a decline of 10.9% within two days [8]. Group 3: Legal Proceedings - Investors who purchased F5 securities between October 28, 2024, and October 27, 2025, are encouraged to apply to be appointed as lead plaintiff in the lawsuit by February 17, 2026 [2][4].

Core Viewpoint - A class action lawsuit has been filed against Jayud Global Logistics Ltd. for allegedly misleading investors regarding the company's business operations and trading activities during the specified class period [8]. Allegation Details - The lawsuit claims that Jayud's management made materially false and misleading statements and failed to disclose significant adverse facts about the company [3]. - Specific allegations include: 1. Jayud was involved in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals [3]. 2. Insiders and affiliates allegedly used offshore or nominee accounts to coordinate the dumping of shares during a price inflation campaign [3]. 3. The company's public statements and risk disclosures did not mention false rumors and artificial trading activity that influenced the stock price [3]. 4. As a result, the positive statements made by the defendants regarding the company's business and prospects were misleading and lacked a reasonable basis [3]. Next Steps - Investors who purchased Jayud shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 19, 2026 [8].

Core Viewpoint - A class action lawsuit has been filed against Klarna Group plc for allegedly misleading investors regarding the company's financial health and risk disclosures related to its IPO on September 10, 2025 [8]. Allegation Details - The lawsuit claims that Klarna's Registration Statement contained false and misleading statements, particularly regarding the underestimation of loss reserves that were expected to increase shortly after the IPO [8]. - It is alleged that the defendants either knew or should have known about the risks associated with the company's buy now, pay later (BNPL) loans, which were not adequately disclosed [8]. Financial Impact - Klarna's IPO involved the sale of 34,311,274 shares at a price of $40.00 each [8]. - Following the announcement of disappointing Q3 2025 financial results on November 18, 2025, which included a significant rise in credit loss provisions, Klarna's share price fell by $3.25, or approximately 9.3%, from $34.88 to $31.63 [8].